Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say
Executive Summary
Brand and generic drug trade associations disagree with FDA’s proposal to have biosimilar sponsors pay a product development fee before even submitting a marketing application.
You may also be interested in...
Accelerated Approval Could Expand As Alternative To Progressive Approval
CDER Director Woodcock says agency should issue internal and external guidance to promote consistent use of the pathway.
Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost
Tentative agreement closely resembles FDA's original proposal.
Biosimilar User Fee Negotiations Hit Snag With GPhA Gambit For Lower Fees
The Generic Pharmaceutical Association is balking at continuing to negotiate the design of a biosimilar user fee program that is independent of other user fees and has its own baseline appropriations trigger.